VIRAX BIOLABS GROUP LTD (VRAX)
KYG9495L1251 - Common Stock
Taking everything into account, VRAX scores 4 out of 10 in our fundamental rating. VRAX was compared to 108 industry peers in the Health Care Providers & Services industry. The financial health of VRAX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, VRAX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VRAX had negative earnings in the past year.
VRAX had a negative operating cash flow in the past year.
In the past 5 years VRAX always reported negative net income.
VRAX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VRAX's Return On Assets of -69.69% is on the low side compared to the rest of the industry. VRAX is outperformed by 90.65% of its industry peers.
The Return On Equity of VRAX (-76.12%) is worse than 73.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.69% | ||
| ROE | -76.12% | ||
| ROIC | N/A |
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 39.58%, VRAX is doing good in the industry, outperforming 67.29% of the companies in the same industry.
VRAX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRAX has more shares outstanding
The debt/assets ratio for VRAX is higher compared to a year ago.
2.2 Solvency
VRAX has an Altman-Z score of 5.73. This indicates that VRAX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.73, VRAX belongs to the top of the industry, outperforming 89.72% of the companies in the same industry.
A Debt/Equity ratio of 0.06 indicates that VRAX is not too dependend on debt financing.
The Debt to Equity ratio of VRAX (0.06) is better than 76.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.73 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
VRAX has a Current Ratio of 11.58. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
VRAX's Current ratio of 11.58 is amongst the best of the industry. VRAX outperforms 99.07% of its industry peers.
VRAX has a Quick Ratio of 11.40. This indicates that VRAX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 11.40, VRAX belongs to the top of the industry, outperforming 99.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 11.58 | ||
| Quick Ratio | 11.4 |
3. Growth
3.1 Past
VRAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.26%, which is quite impressive.
The Revenue has been growing slightly by 7.02% in the past year.
The Revenue has been growing by 9.24% on average over the past years. This is quite good.
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
Revenue 1Y (TTM)7.02%
Revenue growth 3Y9.24%
Revenue growth 5YN/A
Sales Q2Q%-93.53%
3.2 Future
VRAX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.68% yearly.
The Revenue is expected to grow by 210.44% on average over the next years. This is a very strong growth
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
VRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 42.65, which means the current valuation is very expensive for VRAX.
VRAX's Price/Forward Earnings is on the same level as the industry average.
VRAX is valuated expensively when we compare the Price/Forward Earnings ratio to 23.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.65 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VRAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
VRAX's earnings are expected to grow with 48.68% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.68%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VRAX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIRAX BIOLABS GROUP LTD
NASDAQ:VRAX (12/23/2024, 10:56:47 AM)
1.74
-0.01 (-0.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.75%
Inst Owner ChangeN/A
Ins Owners7.07%
Ins Owner ChangeN/A
Market Cap7.55M
AnalystsN/A
Price Target20.4 (1072.41%)
Short Float %3.57%
Short Ratio0.07
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 42.65 | ||
| P/S | 88.98 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.87 | ||
| P/tB | 0.87 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.6
EYN/A
EPS(NY)0.04
Fwd EY2.34%
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.02
BVpS1.99
TBVpS1.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.69% | ||
| ROE | -76.12% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.58% | ||
| FCFM | N/A |
ROA(3y)-1199.47%
ROA(5y)-1754.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 289.15% | ||
| Cap/Sales | 829.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 11.58 | ||
| Quick Ratio | 11.4 | ||
| Altman-Z | 5.73 |
F-Score4
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.81%
EPS Next Y68.42%
EPS Next 2Y48.68%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)7.02%
Revenue growth 3Y9.24%
Revenue growth 5YN/A
Sales Q2Q%-93.53%
Revenue Next Year477.17%
Revenue Next 2Y210.44%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-70.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.46%
OCF growth 3YN/A
OCF growth 5YN/A